09/06/2024 | Press release | Distributed by Public on 09/06/2024 14:11
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As part of the continuing efforts of FibroGen, Inc. (the "Company") to implement a significant cost reduction plan in the U.S., which was initiated on August 2, 2024, the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer. Mr. Graham's planned departure date is December 15, 2024 and Dr. Adib's planned departure date is November 1, 2024. The Company would like to thank Mr. Graham and Dr. Adib for their service and for the many contributions they made as Chief Financial Officer and Chief Medical Officer, respectively, and as members of the executive team. The employment decisions for Mr. Graham and Dr. Adib are not the result of any disagreement with the Company.